{"corpus_id":207577951,"paper_sha":"f15bcb79fe75c3ada3446f620397b152499f9c8b","doi":"10.1159/000479976","arxiv_id":null,"pmid":28898890,"pmcid":null,"mag_id":2754271091,"dblp_id":null,"acl_id":null,"title":"An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)","year":2017,"publication_date":"2017-09-01","venue":"Respiration","journal":{"name":"Respiration","pages":"408 - 415","volume":"94"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Clinical Trial, Phase III","Journal Article","Multicenter Study"],"s2_fields_of_study":["Medicine"],"reference_count":27,"citation_count":135,"influential_citation_count":3,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Anti-Inflammatory Agents, Non-Steroidal","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D000894"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Idiopathic Pulmonary Fibrosis","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"mortality","mj":false,"ui":"Q000401"}],"ui":"D054990"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Pyridones","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":true,"ui":"Q000009"}],"ui":"D011728"}],"chemicals":[{"n":"Anti-Inflammatory Agents, Non-Steroidal","ui":"D000894","reg":"0"},{"n":"Pyridones","ui":"D011728","reg":"0"},{"n":"pirfenidone","ui":"C093844","reg":"D7NLD2JX7U"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.karger.com/Article/Pdf/479976","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/f15bcb79fe75c3ada3446f620397b152499f9c8b","s2_open_access_license":"CCBYNCND","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Background: RECAP (NCT00662038) was an open-label extension study in patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) 016 phase 3 trial or the Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY) 004/006 phase 3 trials. Objective: To obtain long-term safety data for pirfenidone in patients with IPF in RECAP. Methods: Of the 1,334 patients who participated in the phase 3 trials, 1,058 entered RECAP. The final analysis from enrollment (September 2008) to June 2015 is presented. Results: Mean (SD) and median (range) pirfenidone exposures in RECAP were 122 (98) weeks and 88 (>0 to 349) weeks, respectively, with a mean daily dose of 2,091.1 mg. Cumulative total exposure was 2,482 patient exposure years (PEY). The treatment-emergent adverse event (TEAE) rate was 701.9 per 100 PEY. The serious TEAE rate was 53.5 per 100 PEY, with the most common serious TEAE being IPF (11.1 per 100 PEY). Of the 231 deaths (9.3 per 100 PEY), the most common cause was IPF (5.4 per 100 PEY). The treatment discontinuation rate due to a TEAE was 17.9 per 100 PEY; discontinuations were due to IPF (7.2 per 100 PEY), pneumonia, respiratory failure, acute respiratory failure, rash (0.5 per 100 PEY each), and nausea (0.4 per 100 PEY). For patients from CAPACITY 004/006 who entered RECAP, the mean change in percent predicted forced vital capacity from RECAP baseline at 180 weeks was -9.6%. Median on-treatment survival from the first pirfenidone dose in RECAP was 77.2 months. Conclusions: RECAP provides long-term follow-up and safety data for pirfenidone that were consistent with the known profile, with no new safety signals observed.","claims":[{"public_id":"cl_337767d435ab802329833c4112d4ec77","status":"active","text":"Mean pirfenidone exposure in RECAP was 122 weeks, median exposure was 88 weeks, and cumulative exposure reached 2,482 patient exposure years.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_337767d435ab802329833c4112d4ec77"},{"public_id":"cl_dc65e207b29518898a580f535e2567bb","status":"active","text":"No new safety signals were observed and the safety profile was consistent with the known profile of pirfenidone.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_dc65e207b29518898a580f535e2567bb"},{"public_id":"cl_5115e7d84618217ac4a17ebc5bc256a7","status":"active","text":"RECAP provided long-term follow-up safety data for pirfenidone in patients with idiopathic pulmonary fibrosis after completion of ASCEND 016 or CAPACITY 004/006 phase 3 trials.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5115e7d84618217ac4a17ebc5bc256a7"},{"public_id":"cl_3dc6dba8d173c9e851fd59127c5af28c","status":"active","text":"Treatment-emergent adverse events occurred at a rate of 701.9 per 100 patient exposure years, serious treatment-emergent adverse events at 53.5 per 100 patient exposure years, and treatment discontinuations due to adverse events at 17.9 per 100 patient exposure years.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_3dc6dba8d173c9e851fd59127c5af28c"}],"concepts":[{"public_id":"co_09efc98f2274b71be61e0eab17900867","status":"active","name":"safety signal","description":"A newly detected or unexpected potential safety concern arising from clinical data.","types":["safety assessment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_09efc98f2274b71be61e0eab17900867"},{"public_id":"co_132c3f87967fdbf31b44890574f956c8","status":"active","name":"treatment-emergent adverse event","description":"An adverse event that appears or worsens after treatment begins.","types":["outcome","safety event"],"aliases":["TEAE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_132c3f87967fdbf31b44890574f956c8"},{"public_id":"co_19febba12894bfb98417cc99d7df6167","status":"active","name":"patient exposure years","description":"A measure of cumulative treatment exposure expressed as the number of patients observed for one year.","types":["measurement"],"aliases":["PEY"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_19febba12894bfb98417cc99d7df6167"},{"public_id":"co_20958a9c7a661e7b4aacb3f77cf02b55","status":"active","name":"ASCEND 016 phase 3 trial","description":"A phase 3 clinical trial whose completers were eligible to enter RECAP.","types":["clinical trial"],"aliases":["ASCEND 016"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_20958a9c7a661e7b4aacb3f77cf02b55"},{"public_id":"co_3fcf86768265b02a3ec265fa6dd7d35d","status":"active","name":"safety profile","description":"The overall pattern of adverse events and tolerability associated with a treatment.","types":["outcome","safety assessment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3fcf86768265b02a3ec265fa6dd7d35d"},{"public_id":"co_62ba19fa7183c95ff08782ba5d7e6eb8","status":"active","name":"CAPACITY 004/006 phase 3 trials","description":"Two phase 3 clinical trials whose completers were eligible to enter RECAP.","types":["clinical trial"],"aliases":["CAPACITY 004/006"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_62ba19fa7183c95ff08782ba5d7e6eb8"},{"public_id":"co_66c5855c14a9e655a5ff3d273fcb9275","status":"active","name":"idiopathic pulmonary fibrosis","description":"A progressive fibrosing interstitial lung disease studied as the condition treated with pirfenidone.","types":["disease","condition"],"aliases":["IPF"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_66c5855c14a9e655a5ff3d273fcb9275"},{"public_id":"co_6a234aad5349faa70a29c4e70d260d94","status":"active","name":"serious treatment-emergent adverse event","description":"A treatment-emergent adverse event classified as serious.","types":["outcome","safety event"],"aliases":["serious TEAE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6a234aad5349faa70a29c4e70d260d94"},{"public_id":"co_7409daee74d4701ab4dfd47abdcc218f","status":"active","name":"pirfenidone","description":"An antifibrotic drug evaluated here for long-term safety in idiopathic pulmonary fibrosis.","types":["drug","treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7409daee74d4701ab4dfd47abdcc218f"},{"public_id":"co_bb2628c3df9c561b3f862768f2fd8216","status":"active","name":"RECAP","description":"An open-label extension study that followed patients with idiopathic pulmonary fibrosis who had completed prior pirfenidone phase 3 trials.","types":["clinical study","open-label extension study"],"aliases":["NCT00662038"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bb2628c3df9c561b3f862768f2fd8216"},{"public_id":"co_bdca3550c2091eb829f80a36c41d52fc","status":"active","name":"treatment discontinuation due to a TEAE","description":"Stopping treatment because of a treatment-emergent adverse event.","types":["outcome","safety event"],"aliases":["discontinuation due to a TEAE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bdca3550c2091eb829f80a36c41d52fc"}],"external_ids":{"DOI":"10.1159/000479976","ArXiv":null,"PubMed":28898890,"PubMedCentral":null,"MAG":2754271091,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.karger.com/Article/Pdf/479976","landing_url":"https://www.semanticscholar.org/paper/f15bcb79fe75c3ada3446f620397b152499f9c8b","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631873,"paper_uid":"70748791-8eea-45ad-ae6a-52c6463a9f73","canonical_identity":{"paper_id":631873,"paper_uid":"70748791-8eea-45ad-ae6a-52c6463a9f73","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/207577951"}